goserelin + aromatase inhibitor + palbociclib

This combination therapy is a neoadjuvant regimen investigated in the PREDIX LumB trial for patients with estrogen receptor-positive (ER+), HER2-negative early-stage breast cancer. It consists of palbociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), combined with intensive endocrine therapy. The endocrine component includes goserelin, a gonadotropin-releasing hormone (GnRH) agonist used for ovarian function suppression in premenopausal women, and an aromatase inhibitor (such as letrozole, anastrozole, or exemestane) to block the peripheral conversion of androgens to estrogens. By simultaneously targeting the estrogen receptor pathway and the cell cycle machinery, the regimen aims to achieve superior tumor response compared to standard chemotherapy or endocrine therapy alone.

Brand names

Ibrance

Other names

Palbociclib plus endocrine therapyPREDIX LumB regimenPalbociclib + Goserelin + AI